#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians should recognize that cannabis vaping may accelerate the onset of cannabinoid hyperemesis syndrome (CHS), a condition characterized by severe cyclic vomiting that can lead to dehydration and hospitalizations, requiring prompt diagnosis and patient counseling about consumption methods. Patients using vape cartridges should be informed that this delivery method’s rapid absorption and high potency may increase CHS risk compared to other cannabis forms, enabling early symptom recognition and cessation before severe complications develop. This finding supports clinicians’ need to take detailed cannabis use histories that specify consumption method when evaluating patients with recurrent vomiting of unclear etiology.
A recent study from Seattle has identified a significant association between vaporized cannabis consumption via electronic cartridges and accelerated onset of cannabinoid hyperemesis syndrome, commonly referred to as “scromiting” disorder due to its characteristic severe vomiting episodes. The research suggests that the rapid onset and high bioavailability of inhaled cannabis from vape products may contribute to faster development of this paradoxical condition, which presents with cyclic vomiting, abdominal pain, and compulsive hot bathing despite chronic cannabis use. This finding is particularly relevant as vaping has become an increasingly popular consumption method among patients, often perceived as safer or more discreet than smoking, yet may carry distinct risks for certain adverse effects. Clinicians should be aware that patients presenting with severe, recurrent nausea and vomiting should be questioned specifically about vaping frequency and duration, as cannabis hyperemesis syndrome remains underdiagnosed and the diagnosis relies primarily on clinical recognition and cessation of use. The only definitive treatment remains complete cannabis abstinence, though cessation can be challenging given addiction potential and symptom severity. Patients considering or currently using vape cartridges should be counseled about this emerging risk, particularly those with personal or family histories of cyclical vomiting or other cannabinoid sensitivity indicators.
“What we’re seeing clinically is that high-potency vaporized cannabis bypasses the body’s natural feedback mechanisms, delivering cannabinoids to the bloodstream so rapidly that patients don’t recognize the dose escalation until they’re locked into a cycle of CHS symptoms. The speed of onset with vaping means patients reach hyperemesis faster than with other routes, and that matters for counseling and prevention.”
🤢 Cannabis hyperemesis syndrome (CHS) represents a paradoxical and poorly understood adverse effect characterized by cyclic nausea, vomiting, and abdominal pain that may worsen with continued cannabis use despite initial symptomatic relief. The observation that vaping may accelerate CHS onset compared to other consumption methods warrants clinical attention, particularly given the rising popularity of vape cartridges and their typically higher tetrahydrocannabinol concentrations. However, important confounders remain inadequately controlled in much of the CHS literature, including product potency and composition, user dose and frequency, individual genetic susceptibility, and the role of synthetic cannabinoids or contaminants in cartridges. Healthcare providers should maintain a high index of suspicion for CHS in patients presenting with intractable nausea and vomiting, particularly younger adults with regular cannabis use, and should specifically inquire about consumption method and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: